Investment objective & strategy
As of April 24, 2025 · prospectusObjective. The fund seeks long-term capital appreciation.
Strategy. The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed health sciences). Any derivatives that provide exposure to the investment focus suggested by the funds name, or to one or more market risk factors associated with the investment focus suggested by the funds name, are counted (as applicable) toward compliance with the funds 80% investment policy. While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund defines … The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the common stocks of companies engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences (collectively termed health sciences). Any derivatives that provide exposure to the investment focus suggested by the funds name, or to one or more market risk factors associated with the investment focus suggested by the funds name, are counted (as applicable) toward compliance with the funds 80% investment policy. While the fund can invest in companies of any size, the majority of fund assets are expected to be invested in large- and mid-cap companies. The fund defines the health sciences industry broadly and divides it into four main areas: pharmaceutical companies; health care services companies; medical products and devices providers; and biotechnology firms. The funds allocation among these four areas will vary depending on the relative potential the adviser sees within each area and the outlook for the overall health sciences sector. The fund uses fundamental, bottom-up analysis that seeks to identify high-quality companies and the most compelling investment opportunities. In general, the fund follows a growth investment strategy, seeking companies whose earnings are expected to grow faster than inflation and the economy in general. When stock valuations seem unusually high, however, a value approach, which gives preference to seemingly undervalued companies, may be emphasized. The fund generally seeks investments in companies that are developing new and effective medicines, as well as companies whose business models reduce costs or improve quality in health care systems. While most assets are typically invested in U.S. common stocks, the fund may invest in foreign stocks in keeping with its objective(s). The funds investments may include holdings in privately held companies and companies that only recently began to trade publicly.
Top holdings
As of March 31, 2026 · N-PORT| Security | Ticker | Value | % of fund |
|---|---|---|---|
| LILLY ELI and CO | — | $67.69M | 10.21% |
| THERMO FISHER SCIENTIFIC INC | — | $27.01M | 4.08% |
| INTUITIVE SURGICAL INC | — | $24.40M | 3.68% |
| STRYKER CORP | — | $23.12M | 3.49% |
| MERCK & CO | — | $22.91M | 3.46% |
| ASTRAZENECA PLC | — | $21.05M | 3.18% |
| UNITEDHEALTH GRP | — | $20.54M | 3.10% |
| ARGENX SE SPONSORED ADR | — | $19.39M | 2.93% |
| ABBVIE INC | — | $19.08M | 2.88% |
| REGENERON PHARMACEUTICALS INC | — | $17.77M | 2.68% |
Portfolio moves
Dec 31, 2025 → Mar 31, 2026How many positions this fund opened, exited, grew, trimmed, or left unchanged between its two most recent N-PORT snapshots — net changes between point-in-time reports, not a trade log.
Similar funds
Funds whose portfolios most overlap this one, by weight| Fund | Overlap | Net exp. |
|---|---|---|
| T. Rowe Price Health Sciences Fund, Inc. · PRHSX, THISX | 99% | 0.68% |
| EQ/T.Rowe Price Health Sciences Portfolio | 95% | 0.95% |
| Health Sciences Trust · JAFMX, JEHSX, JAFKX | 88% | 0.84% |
Advisers
| Firm | Role |
|---|---|
| T. Rowe Price Associates, Inc. | Adviser |
Footnotes
- Expense ratio as of April 24, 2025, from the fund's prospectus.
- Net assets and holdings count as of March 31, 2026, from the fund's N-PORT filing.
- Total return for calendar year 2025, before tax and after fund expenses. Computed by compounding the twelve monthly total returns the fund reported in its SEC N-PORT filings for 2025 (the latest prospectus does not yet chart this year).
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.